HLS Therapeutics Inc's stock is on the rise, reflecting investor optimism and solid performance metrics.
In the latest trading session, HLS Therapeutics Inc (HLS.TO) saw its stock price increase by 1.99%, closing at CA$4.37. This upward movement comes alongside positive financial results and strategic product launches, positioning the company well in the competitive pharmaceutical landscape.
Investor takeaway: Investors should note HLS Therapeutics' recent revenue growth and product expansion as key drivers behind today's stock performance, suggesting a potential for continued upward momentum.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.29
+76.9% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc sees a 1.99% gain in one trading day
Advertisement
The stock's rise to CA$4.37 reflects growing investor confidence, supported by recent financial performance and product launches.
Bull case
The company reported a 15% increase in net sales for Vascepa and launched NILEMDO™, which could significantly boost its revenue. Additionally, analysts have an average rating of 'Buy' with a price target of CA$7.35, indicating strong confidence in the company's future growth.
Bear case
Despite the positive performance, HLS Therapeutics has a negative profit margin and fluctuating revenue trends that could pose risks. Investors should stay cautious about the company's ability to sustain growth in a volatile market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
